Meeting
2017 ASCO Annual Meeting
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
Authors
Jesus G. Berdeja
Sarah Cannon Research Institute, Nashville, TN
Jesus G. Berdeja , Yi Lin , Noopur S. Raje , David Samuel DiCapua Siegel , Nikhil C. Munshi , Michaela Liedtke , Sundar Jagannath , Marcela Valderrama Maus , Ashley Turka , Lyh Ping Lam , Kristen Hege , Richard Morgan , M. Travis Quigley , James Kochenderfer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Cellular Immunotherapy
Clinical Trial Registration Number
NCT02658929
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3010)
DOI
10.1200/JCO.2017.35.15_suppl.3010
Abstract #
3010
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies.
First Author: Ross Firestone
Poster
2019 ASCO Annual Meeting
The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
First Author: Lu Han
Poster
2018 ASCO Annual Meeting
Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
First Author: Yarong Liu
Poster
2016 ASCO Annual Meeting
Towards a safer CD19 CART therapy with reduced risk of cytokine release syndrome (CRS).
First Author: Lucas H. Horan